Chief Operating Officer Morais Mark A. converted options into 725 shares and sold $2,016 worth of shares (203 units at $9.93), increasing direct ownership by 1% to 35,596 units (SEC Form 4)

$FTRE
Medical Specialities
Health Care
Get the next $FTRE alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Morais Mark A.

(Last) (First) (Middle)
8 MOORE DRIVE

(Street)
DURHAM NC 27709

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fortrea Holdings Inc. [ FTRE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/12/2025 M 725 A $0(1) 35,799 D
Common Stock(2) 03/13/2025 S 203 D $9.93(3) 35,596(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 03/12/2025 M 725 (5) (5) Common Stock 725 $0 115,234(6) D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU"), subject to the achievement of performance goals, represents the contingent right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of the performance-based RSUs into Common Stock subject to the achievement of certain performance goals as approved by the Management Development and Compensation Committee.
2. The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
3. This transaction was executed in multiple trades at prices ranging from $9.82 to $10.02. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This number reflects the aggregate amount of Common Stock held by the reporting person.
5. In connection with the spin-off of Fortrea by Laboratory Corporation of America Holdings ("Labcorp"), 50% of the performance awards granted by Labcorp in 2022 for the three-year performance period through December 31, 2024 were converted into RSUs of Fortrea and 50% were converted to Fortrea performance share awards subject to the original three-year vesting period pursuant to the terms of the Employee Matters Agreement. These performance-based awards vested on March 12, 2025.
6. This number reflects the aggregate number of time-vesting and performance based RSUs held by the reporting person.
/s/ James Stillman Hanson, Attorney-in-Fact for Mark A. Morais 03/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $FTRE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FTRE

DatePrice TargetRatingAnalyst
12/11/2024$30.00 → $23.00Buy → Neutral
Citigroup
12/6/2024$28.00 → $25.00Outperform → Neutral
Robert W. Baird
9/25/2024$25.00 → $21.00Buy → Hold
Jefferies
8/8/2024$31.00 → $27.00Outperform → In-line
Evercore ISI
7/24/2024$30.00Equal Weight
Barclays
6/6/2024$28.00Neutral
Goldman
5/29/2024$27.00Hold
TD Cowen
5/28/2024$27.00Neutral
Mizuho
More analyst ratings

$FTRE
Press Releases

Fastest customizable press release news feed in the world

See more
  • Fortrea Reports Fourth Quarter and Full-Year 2024 Results; Issues Full-Year 2025 Guidance

    For the three months and full-year ended December 31, 2024, from continuing operations: Revenues of $697.0 million for the fourth quarter, $2,696.4 million for the full yearGAAP net loss of $(73.9) million for the fourth quarter, $(271.5) million for the full yearAdjusted EBITDA of $56.0 million for the fourth quarter, $202.5 million for the full yearFourth-quarter book-to-bill ratio of 1.35x DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the fourth quarter and full year ended December 31, 2024. "Our intense focus on our customers' success and creating a

    $FTRE
    Medical Specialities
    Health Care
  • Fortrea to Add Erin L. Russell to Board of Directors

    DURHAM, N.C., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that it will appoint Erin L. Russell, a financial and healthcare executive, as a new independent member of the Company's Board of Directors (the "Board") effective immediately prior to the next regularly scheduled meeting of the Board. Ms. Russell is being appointed in connection with a cooperation agreement (the "Agreement") between Fortrea and Starboard Value LP (together with its affiliates, "Starboard"), an investment firm that owns approximately 5.4% of the Company's outstanding common stock. "We are pleased to have reached a constructive agree

    $EHTH
    $FTRE
    $KAI
    $MODV
    Specialty Insurers
    Finance
    Medical Specialities
    Health Care
  • Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research

    DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficie

    $FTRE
    Medical Specialities
    Health Care

$FTRE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FTRE
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$FTRE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FTRE
SEC Filings

See more

$FTRE
Leadership Updates

Live Leadership Updates

See more
  • Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research

    DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficie

    $FTRE
    Medical Specialities
    Health Care
  • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

    SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

    $BDX
    $FTRE
    $MRVI
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations
  • Fortrea Appoints Robert Parks as Chief Accounting Officer

    DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,

    $FTRE
    Medical Specialities
    Health Care

$FTRE
Financials

Live finance-specific insights

See more
  • Fortrea Reports Fourth Quarter and Full-Year 2024 Results; Issues Full-Year 2025 Guidance

    For the three months and full-year ended December 31, 2024, from continuing operations: Revenues of $697.0 million for the fourth quarter, $2,696.4 million for the full yearGAAP net loss of $(73.9) million for the fourth quarter, $(271.5) million for the full yearAdjusted EBITDA of $56.0 million for the fourth quarter, $202.5 million for the full yearFourth-quarter book-to-bill ratio of 1.35x DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the fourth quarter and full year ended December 31, 2024. "Our intense focus on our customers' success and creating a

    $FTRE
    Medical Specialities
    Health Care
  • Fortrea Announces Date for Fourth Quarter and Full Year 2024 Financial Results and Conference Call

    DURHAM, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Monday, March 3, 2025. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings

    $FTRE
    Medical Specialities
    Health Care
  • Fortrea Reports Third Quarter 2024 Results

    For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 millionGAAP net loss of $(18.5) millionAdjusted EBITDA of $64.2 millionGAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectivelyBook-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the third quarter ended September 30, 2024. "We had a solid quarter of execution" said Tom Pike, chairman and CEO of Fortrea. "Our book-to-bill ratio for the quarter, as exp

    $FTRE
    Medical Specialities
    Health Care

$FTRE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more